Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.
Glazova. Nataliya Yu NY; Manchenko. Daria M DM; Volodina. Maria A MA; Merchieva. Svetlana A SA; Andreeva. Ludmila A LA; Kudrin. Vladimir S VS; Myasoedov. Nikolai F NF; Levitskaya. Natalia G NG
Key Findings
- Neonatal fluvoxamine exposure leads to long‑term anxiety‑like behavior and learning deficits in rats
- Fluoxetine exposure alters monoamine levels in the brain during adolescence and early adulthood
- Post‑exposure treatment with Semax reduces anxiety, improves maze learning, and normalizes brain monoamine levels
Practical Outcomes
- Semax shows promise as a neuroprotective or nootropic agent that could counteract early‑life serotonin disruptions, but human studies are needed. Biohackers might view Semax as a candidate for anxiety or cognition support, yet dosing and safety in people remain unclear, so cautious, evidence‑based use is advised.
Summary
In rats, giving the antidepressant fluvoxamine to newborns caused lasting anxiety, learning problems, and brain chemistry changes. Giving the peptide Semax after the drug exposure reduced anxiety, helped the rats learn better, and fixed the brain chemistry. This suggests Semax might protect the brain from early serotonin‑related disturbances, but the work is only in animals.
Abstract
Selective serotonin reuptake inhibitors (SSRI) are commonly used to treat depression during pregnancy. SSRIs cross the placenta and may influence the maturation of the foetal brain. Clinical and preclinical findings suggest long-term consequences of SSRI perinatal exposure for the offspring. The mechanisms of SSRI effects on developing brain remain largely unknown and there are no directional approaches for prevention of the consequences of maternal SSRI treatment during pregnancy. The heptapeptide Semax (MEHFPGP) is a synthetic analogue of ACTH(4-10) which exerts marked nootropic and neuroprotective activities. The aim of the present study was to investigate the long-term effects of neonatal exposure to the SSRI fluvoxamine (FA) in white rats. Additionally, the study examined the potential for Semax to prevent the negative consequences of neonatal FA exposure. Rat pups received FA or vehicle injections on postnatal days 1-14, a time period equivalent to 27-40 weeks of human foetal age. After FA treatment, rats were administered with Semax or vehicle on postnatal days 15-28. During the 2nd month of life, the rats underwent behavioural testing, and monoamine levels in brain structures were measured. It was shown that neonatal FA exposure leads to the impaired emotional response to stress and novelty and delayed acquisition of food-motivated maze task in adolescent and young adult rats. Furthermore, FA exposure induced alterations in the monoamine levels in brains of 1- and 2- month-old rats. Semax administration reduced the anxiety-like behaviour, improved learning abilities and normalized the levels of brain biogenic amines impaired by the FA exposure. The results demonstrate that early-life FA exposure in rat pups produces long-term disturbances in their anxiety-related behaviour, learning abilities, and brain monoamines content. Semax exerts a favourable effect on behaviour and biogenic amine system of rats exposed to the antidepressant. Thus, peptide Semax can prevent behavioural deficits caused by altered 5-HT levels during development.
Study Information
pubmed
2020
2020-12-28T00:00:00.000Z
10.1016/j.npep.2020.102114
4
112